Tag: Antibody-Drug Conjugate
-
ABBV-706: A Promising Treatment for Relapsed/Refractory SCLC
Introduction to ABBV-706 and Its Significance Small cell lung cancer (SCLC) is a particularly aggressive form of lung cancer characterized by rapid growth and early metastasis. Treatment options for patients with relapsed or refractory SCLC have historically been limited. However, recent advancements, particularly the emergence of novel therapies like ABBV-706, have provided new hope. This…
-
Durable Responses with ABBV-706 in Relapsed/Refractory SCLC
Introduction to ABBV-706 Small cell lung cancer (SCLC) is known for its aggressive nature and poor prognosis, especially in patients who have experienced relapse. Recent advancements in targeted therapies are paving the way for better outcomes. ABBV-706, an antibody-drug conjugate (ADC) that targets the seizure-related homolog protein 6 (SEZ6), has emerged as a potential game-changer.…